<DOC>
	<DOCNO>NCT01167153</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Valsartan/Amlodipine ( EXforge® ) nifedipine , well vascular function index .</brief_summary>
	<brief_title>Effectiveness Valsartan/Amlodipine ( EXforge® ) Nifedipine treAtment coMparison Treating Chinese Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Male female adult outpatient uncontrolled hypertension screen randomization despite current antihypertensive monotherapy ( initial dose Angiotensin Receptor Blockers ( ARB ) , Angiotensin Converting Enzyme Inhibitors ( ACEI ) , Calcium Channel Blockers ( CCB ) , diuretic β receptor blocker ) Systolic BP ( SBP ) level ≥160 mm Hg ( ≥160 mm Hg diabetic ) diastolic BP ( DBP ) level ≥110 mm Hg ( ≥100 mm Hg diabetic ) time screen randomization . Patients type 1 diabetes poorly control type 2 diabetes ( glycosylated hemoglobin &gt; 8.0 % ) Patients evidence hepatic disease renal impairment Other exclusion criterion include evidence secondary hypertension history cardiovascular disease . Women pregnant , nursing , childbearing potential use acceptable contraception . Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Valsartan Amlodipine single pill combination</keyword>
	<keyword>BP control</keyword>
	<keyword>ABPM</keyword>
	<keyword>Hypertensive patient adequately control mono antihypertensive drug</keyword>
</DOC>